| Literature DB >> 28469158 |
Subash Chandra Sonkar1, Kirti Wasnik1, Anita Kumar2, Vineeta Sharma3, Pratima Mittal2, Prashant Kumar Mishra1, Mausumi Bharadwaj3, Daman Saluja4.
Abstract
Utility of syndromic case management (SCM) in women visiting obstetrics & gynecology department needs to be evaluated as it is subjective and imperfect. Consequently, antibiotic resistance has accelerated along with increased risk of infection to the partners. To understand the effectiveness and/or inadequacies of SCM, 11000 women were recruited and examined by clinicians for infection by Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Bacterial vaginosis (BV) and others. Amongst these patients, 1797 (16.3%) reported vaginal discharge (VD). Other symptoms included: vaginitis (97%), cervicitis (75%), genital ulcers (60%), abnormal vaginal discharge (55%) and lower abdominal pain (48%). The patients were treated for single or co-infections using pre-packed National Aids Control Program III STI/RTI Kits. However, based on PCR diagnostics, 1453/1797 (81%) subjects were uninfected for NG/TV/CT. Amongst 344 (19%) infected patients, 257 (75%) carried infection with single pathogen (TV/NG/CT) while 87/344 (25%) were co-infected with multiple pathogens. Prevalence of TV, NG & CT was 4%, 7% and 8% respectively. Co-infection with CT + NG was highest, 51% (44/87), whereas, co-infection with CT + TV was 21% and NG + TV was 18% while co-infection with all three pathogens was 1.3%. We conclude that SCM is imprecise and successful intervention requires accurate and confirmatory diagnostic approach.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28469158 PMCID: PMC5431118 DOI: 10.1038/s41598-017-01422-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
List of primer sets specific for different pathogens used in the present study.
| S. N. | Microorganisms | Gene | Primers Sequences | References |
|---|---|---|---|---|
| 1 |
|
| C2 5′TGATGCTAGGGACGGATTAAAACC3′ |
|
| C5 5′TTCCCCTAAATTATGCGGTGGAA3′ | ||||
| 2 |
|
| F 5′CAACTATTCCCGATTGCGA3′ |
|
| R 5′GTTATACAGCTTCGCCTGAA3′ | ||||
| 3 |
|
| F 5′CAAAGTCAACATGGCTATGAT3′ |
|
| R 5′GAAGACCTGTGTGGATGGATGT3′ |
Figure: 1(A) Distribution of infected and uninfected patients based on PCR diagnostic assay using total genomic DNA isolated from clinical samples. (B) Diagrammatic representation of distribution of infected and uninfected patients for single or mixed infection. The distribution of infection with T. vaginalis, N. gonorrhoeae and C. trachomatis out of the total symptomatic patients enrolled in the study is shown.
Figure 2Venn diagram showing prevalence of T. vaginalis, C. trachomatis and N. gonorrhoeae infection as well as co-infection. DNA was isolated from samples collected from symptomatic patients and infection for these three pathogens was determined by PCR based diagnosis.
Figure 3Age wise distribution of infection by T. vaginalis, C. trachomatis and N. gonorrhoeae as well as their co-infection as determined by PCR. (A) Percent prevalence was determined for patients infected with any of the three pathogens in different age groups as determined by PCR and SCM. (B) Bar diagram to show distribution of infection by T. vaginalis, C. trachomatis and N. gonorrhoeae alone as well as their co-infection in different age groups based on PCR diagnosis.
Management and treatment guidelines for symptomatic patients through syndromic case management.
| S. No | STI/RTI Syndromic Diagonosis | KIT Prescribed | Name of the Drugs |
|---|---|---|---|
| 1 | Urethral Discharge/Ano Rectal Discharge/Cervical Discharge/Presumptive Treatment/Painful Scrotal Swelling | Kit 1 Gray | Azithromycin (1 g) OD STAT and Cefixime (400 mg) OD STAT |
| 2 | Vaginal Discharge (Vaginitis) | Kit 2 Green | Secnidazole (2 g) OD STAT and Fluconazole (150 mg) OD STAT |
| 3 | Genital Ulcer Disease‐ Non Herpetic | Kit 3 White | Benzathine penicillin (2.4 MU) IM STAT and Azithomycin (1 g) OD STAT |
| 4 | Genital Ulcer Disease‐ Non Herpetic(Allergic to Penicillin) | Kit 4 Blue | Doxycycline (100 mg) XBD X 14 DAYS and Azithromycin (1 g) X OD STAT |
| 5 | Genital Ulcer Disease‐ Herpetic | Kit 5 Red | Acyclovir (400 mg)X TDS X 7 DAYS |
| 6 | Lower Abdominal Pain (Pelvic Inflammatory Disease) | Kit 6 Yellow | Cefixime (400 mg) X OD STAT and Metronidazole (400 mg) X BD X 14 DAYS and Doxycycline (100 mg) X BD X 14 DAYS. |
| 7 | Inguinal Bubo | Kit 7 Black | Doxycycline (100 mg)X BD X 21 DAYS and Azithromycin (1 g) X OD STAT |
Figure 4Percent distribution of different symptoms with reference to infections with T. vaginalis, C. trachomatis and N. gonorrhoeae as determined by PCR diagnostics. (A) Percentage of different symptoms amongst patients with vaginal discharge visiting the hospitals. (B) Percentage of different symptoms amongst patients tested positive for any of the three pathogens by PCR diagnostic assays. (C) Percent association of different symptoms among all the infected patients. (D) Relative association of different symptoms in patients infected with either T. vaginalis, or C. trachomatis or N. gonorrhoeae as determined by SCM. (E) Relative association of different symptoms in percent in patients infected with either T. vaginalis, or C. trachomatis or N. gonorrhoeae based on PCR diagnostics.